research Role of plasminogen activator inhibitor type 1 (PAI-1) in PCOS patient 3 citations , August 2017 in “International journal of reproduction, contraception, obstetrics and gynecology” People with PCOS have higher levels of PAI-1, which may increase their risk of heart disease and fertility issues.
research Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women 2 citations , February 2023 in “BMC women's health” Birth control pills change the activity of certain inflammation and blood clotting genes in women with PCOS.
research Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome 29 citations , January 2009 in “Gynecological Endocrinology” Women with PCOS have higher levels of certain blood clotting factors, suggesting a greater risk of cardiovascular issues.
research Wound healing in development 29 citations , September 2012 in “Birth Defects Research” Wounds heal without scarring in early development but later result in scars, and studying Wnt signaling could help control scarring.
research Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries 21 citations , July 2016 in “Gynecological Endocrinology” Obese and non-obese women with PCOS have higher heart risk markers, especially if they are obese.